 |
 |
 |
 |
 |
 |
 |
 |
|
Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunotherapy, monoclonal antibody and small molecule product candidates to treat a wide range of cancers.
The dedication of our research and development team has resulted in our lead product candidate, sipuleucel-T, rapidly approaching commercialization.
Sipuleucel-T, an active cellular immunotherapy, is in late-stage development for the treatment of metastatic, androgen-independent prostate cancer.
Lapuleucel-T, an active cellular immunotherapy, is in development for breast, ovarian and colon cancer.
CEA, an active cellular immunotherapy, is in preclinical development for breast, lung and colon cancer.
CA-9, an active cellular immunotherapy, is in preclinical development for kidney, colon and cervical cancer.
Trp-p8 (also known as Trp-M8), a small molecule, is in preclinical development for prostate cancer.
Print page
Email page